[Helicobacter pylori infection in the HIV + population: a comorbidity to think about].

Szczegóły
Abstrakt

Tytuł:: [Helicobacter pylori infection in the HIV + population: a comorbidity to think about].
Autorzy:: Valencia ME; Mª Eulalia Valencia Ortega, Servicio de Medicina Interna-Unidad de VIH. Hospital Universitario La Paz-IdiPaz. Madrid. Spain. .
Montejano R
Moreno V
Martín Carbonero L
Bernardino JI
Serrano L
Transliterated Title:: Infección por Helicobacter pylori en la población VIH+: una comorbilidad en la que pensar.
Źródło:: Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia [Rev Esp Quimioter] 2020 Feb; Vol. 33 (1), pp. 68-72. Date of Electronic Publication: 2020 Jan 10.
Typ publikacji:: Journal Article
Język:: Spanish; Castilian
Imprint Name(s):: Publication: [Barcelona] : Sociedad Española de Quimioterapia
Original Publication: Barcelona : J.R. Prous, S.A., [1988-
MeSH Terms:: Helicobacter pylori*
HIV Infections/*epidemiology
Helicobacter Infections/*epidemiology
Adult ; Amoxicillin/therapeutic use ; Anti-Bacterial Agents/therapeutic use ; Anti-HIV Agents/therapeutic use ; Anti-Ulcer Agents/therapeutic use ; Clarithromycin/therapeutic use ; Comorbidity ; Drug Therapy, Combination ; Dyspepsia/etiology ; Female ; Gastritis, Atrophic/epidemiology ; HIV Infections/drug therapy ; Helicobacter Infections/complications ; Helicobacter Infections/drug therapy ; Humans ; Male ; Metronidazole/therapeutic use ; Middle Aged ; Omeprazole/therapeutic use ; Retrospective Studies ; Spain/epidemiology
References:: Gastroenterol Hepatol. 2018 Apr;41(4):272-280. (PMID: 29426621)
Gastroenterol Hepatol. 2016 Sep;39 Suppl 1:36-46. (PMID: 27888863)
Clin Gastroenterol Hepatol. 2018 Jul;16(7):992-1002.e6. (PMID: 29559361)
PeerJ. 2017 May 30;5:e3392. (PMID: 28584718)
Am J Gastroenterol. 2017 Feb;112(2):212-239. (PMID: 28071659)
Am Fam Physician. 2011 Jun 15;83(12):1443-51. (PMID: 21671545)
Gastroenterol Hepatol. 2016 Dec;39(10):697-721. (PMID: 27342080)
Helicobacter. 2014 Oct;19(5):323-9. (PMID: 24773336)
Med Clin (Barc). 2017 Jan 6;148(1):20-22. (PMID: 27916266)
Gastroenterology. 2017 Aug;153(2):420-429. (PMID: 28456631)
J Clin Pharmacol. 2008 Jan;48(1):60-5. (PMID: 18094220)
PLoS One. 2015 Nov 24;10(11):e0143388. (PMID: 26599971)
HIV Clin Trials. 2014 Jan-Feb;15(1):27-35. (PMID: 24518212)
PLoS One. 2015 Dec 21;10(12):e0145119. (PMID: 26691198)
Ann Parasitol. 2019;65(1):3-17. (PMID: 31054561)
Gastroenterology Res. 2018 Apr;11(2):95-99. (PMID: 29707075)
Contributed Indexing:: Keywords: Antiretroviral Therapy; HIV; Helicobacter pylori
Substance Nomenclature:: 0 (Anti-Bacterial Agents)
0 (Anti-HIV Agents)
0 (Anti-Ulcer Agents)
140QMO216E (Metronidazole)
804826J2HU (Amoxicillin)
H1250JIK0A (Clarithromycin)
KG60484QX9 (Omeprazole)
Entry Date(s):: Date Created: 20200115 Date Completed: 20201228 Latest Revision: 20201228
Update Code:: 20240105
PubMed Central ID:: PMC6987630
DOI:: 10.37201/req/033.2019
PMID:: 31933346
: Czasopismo naukowe

Full Text Finder

Objective: Gastrointestinal disorders are frequent in HIV+. Helicobacter pylori may be an underdiagnosed cause.
Methods: Patients with HIV and H. pylori were described since January 1998 up to December 2017.
Results: A total de 132 patients were included. The most frequent symptom was dyspepsia. 88.5% had chronic atrophic gastritis. Eradication was achieved in 102 (77.3%). Healing was more frequent with quadruple regimen (p=0.004) and in the youngest (p=0.041).
Conclusions: H. pylori infection could be responsible for nonspecific digestive manifestations in HIV + patients.
(©The Author 2020. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).)

Informacja